# PolyPeptide Laboratories, Inc., Torrance, CA – FDA Inspections

Source: https://www.keypedia.com/companies/polypeptide-laboratories-inc/9d05664c-4a42-45cc-81f6-ef85c356ecc1

> Inspection records and compliance data for PolyPeptide Laboratories, Inc. in Torrance, California. 10 FDA inspections on record, 2 Form 483s, last inspected May 10, 2024.

---

## Details

- Name: PolyPeptide Laboratories, Inc.
- FEI Number: 1000519239
- Business Operations: API MANUFACTURE
- Address Line 1: 365 Maple Ave
- City: Torrance
- State: California
- Zip Code: 90503
- Country Name: United States
- Address: 365 Maple Ave, Torrance, California 90503, United States
- Country: United States

## Related Documents

- [483 - PolyPeptide Laboratories, Inc. - 2024-05-10](https://www.keypedia.com/records/483/polypeptide-laboratories-inc/ba06b162-f067-4036-abb1-01c2e728f3fa) — source: FDA, date: May 10, 2024
- FDA Inspection 1246171 - PolyPeptide Laboratories, Inc. - 2024-05-10 — classification: Voluntary Action Indicated (VAI), source: FDA, date: May 10, 2024
- [FDA Inspection 1246171 - PolyPeptide Laboratories, Inc. - 2024-05-10](https://www.keypedia.com/records/fda_inspections/polypeptide-laboratories-inc/f50ba29e-e3b8-44a9-a050-0b7c0ebf6f77) — classification: Voluntary Action Indicated (VAI), source: FDA, date: May 10, 2024
- [EIR - PolyPeptide Laboratories, Inc. - 2021-11-19](https://www.keypedia.com/records/eir/polypeptide-laboratories-inc/19c17707-3c4a-4370-88b5-950e514b5073) — source: FDA, date: November 19, 2021
- [FDA Inspection 1159374 - PolyPeptide Laboratories, Inc. - 2021-11-19](https://www.keypedia.com/records/fda_inspections/polypeptide-laboratories-inc/af021466-df72-405e-9b69-bdd15df330cb) — classification: No Action Indicated (NAI), source: FDA, date: November 19, 2021
- FDA Inspection 1159374 - PolyPeptide Laboratories, Inc. - 2021-11-19 — classification: No Action Indicated (NAI), source: FDA, date: November 19, 2021
- [EIR - PolyPeptide Laboratories, Inc. - 2019-08-30](https://www.keypedia.com/records/eir/polypeptide-laboratories-inc/2fafb6c5-c8a8-43fe-8328-27c4b5e0ba13) — source: FDA, date: August 30, 2019
- [483 - PolyPeptide Laboratories, Inc. - 2019-08-30](https://www.keypedia.com/records/483/polypeptide-laboratories-inc/b5e10f52-9c04-4a4d-8237-3a02d497c9b9) — source: FDA, date: August 30, 2019
- [FDA Inspection 1103072 - PolyPeptide Laboratories, Inc. - 2019-08-30](https://www.keypedia.com/records/fda_inspections/polypeptide-laboratories-inc/f8241a25-900b-41ee-ac9d-b8177058c42d) — classification: Voluntary Action Indicated (VAI), source: FDA, date: August 30, 2019
- [FDA Inspection 1021060 - PolyPeptide Laboratories, Inc. - 2017-07-19](https://www.keypedia.com/records/fda_inspections/polypeptide-laboratories-inc/bb82abf9-badf-4502-823c-de13bd77dffb) — classification: Voluntary Action Indicated (VAI), source: FDA, date: July 19, 2017
- FDA Inspection 1021060 - PolyPeptide Laboratories, Inc. - 2017-07-19 — classification: Voluntary Action Indicated (VAI), source: FDA, date: July 19, 2017
- FDA Inspection 953881 - PolyPeptide Laboratories, Inc. - 2015-12-03 — classification: No Action Indicated (NAI), source: FDA, date: December 3, 2015
- [FDA Inspection 953881 - PolyPeptide Laboratories, Inc. - 2015-12-03](https://www.keypedia.com/records/fda_inspections/polypeptide-laboratories-inc/d741dbc5-ed38-47f1-9fa7-51aa6f144e90) — classification: No Action Indicated (NAI), source: FDA, date: December 3, 2015
- FDA Inspection 827287 - PolyPeptide Laboratories, Inc. - 2013-04-12 — classification: No Action Indicated (NAI), source: FDA, date: April 12, 2013

## Related Companies

- [Livzon Group (Ningxia) Pharmaceutical Co., Ltd.](https://www.keypedia.com/companies/livzon-group-ningxia-pharmaceutical-co-ltd/78a1f9d4-41d0-440a-87bc-8c9521d0159a)
- [Novacyl](https://www.keypedia.com/companies/novacyl/928b015a-ee45-4383-ad21-070b43308727)
- [Zhejiang Jiuzhou Pharmaceutical Co., Ltd.](https://www.keypedia.com/companies/zhejiang-jiuzhou-pharmaceutical-co-ltd/6ff21ff3-4c18-4e07-9c38-79e499bfb8fa)
- [Bachem Americas, Inc.](https://www.keypedia.com/companies/bachem-americas-inc/3a9656ad-737b-4682-9ab3-951b1041002e)
- [Shandong Xinhua Pharmaceutical Co., Ltd.](https://www.keypedia.com/companies/shandong-xinhua-pharmaceutical-co-ltd/acea3619-5739-4a9f-a4b2-82e0207194b3)
- [Livzon New North River Pharmaceutical Co., Ltd.](https://www.keypedia.com/companies/livzon-new-north-river-pharmaceutical-co-ltd/49cdcdc8-9c6c-4486-b6cd-e404c21dd2d2)
- [Dottikon Exclusive Synthesis AG](https://www.keypedia.com/companies/dottikon-exclusive-synthesis-ag/db7bdf8b-bd88-416f-94f2-62f946e90074)
- [Cosma SPA](https://www.keypedia.com/companies/cosma-spa/14f96eaf-912e-4eed-af27-43ec40d9b7b7)
- [Cambrex Charles City, Inc.](https://www.keypedia.com/companies/cambrex-charles-city-inc/b14d342b-e5ae-4df6-ad7a-39cd62dfb9c6)
- [BioSpectra, Inc.](https://www.keypedia.com/companies/biospectra-inc/ffb13a38-4f04-49cb-a6fe-fd55f544fcf0)

## Related Officers

- [https://www.fda.gov/media/120628/download](https://www.keypedia.com/people/santiago-gallardo-johnson/f5086b0c-c8fc-44dd-8d12-6506b9dd313f)
- [company_representative](https://www.keypedia.com/people/alexandra-limon/1a8f1851-33b8-4e50-b774-7b13bcb6fffa)
- [recipient](https://www.keypedia.com/people/timothy-f-culbreth/38e0baad-e35c-4528-bbc3-b43561c51c8d)